Latest Science Archives - Page 7 of 8

Rational Design and Optimization of a Potent IDO1 PROTAC

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors...

Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies...

Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...

Developing Resistant Models to Diverse ADC Drugs

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

Advanced On-bead DEL Technology for Enhanced Drug Discovery Screening

DNA-encoded library (DEL) technology has been recognized as a major screening method with unique advantages for offering vast chemical diversity...

Accelerating CIP Discovery with ASMS and DEL

Chemical inducers of proximity (CIPs) are small molecules that induce the proximity of two biological targets, usually proteins. Molecular glues...

Discovery of a Novel Covalent Inhibitor Using DEL

With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets. Covalent drugs...

DEL Screening to Discover Small Molecule Ligands for RNA

RNA-targeted therapeutics are highly intriguing due to their unique physiological properties and novel modes of action in drug R&D. Developing...

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...